Kairos Pharma Ltd. (NYSE American: KAPA) provided a mid-year 2026 update, highlighting plans to expand its oncology pipeline through the proposed acquisition of worldwide rights to CL-741, a Phase 1-ready oral c-MET kinase inhibitor from Celyn Therapeutics. CL-741 targets EGFR-mutated lung cancer and other cancers, and the company expects it to complement its existing portfolio, which includes ENV-105, KROS-201, KROS-102 and ENV-205.
Kairos Pharma intends to initiate a Phase 1 study of CL-741, advance ongoing clinical trials of ENV-105 in prostate cancer and non-small cell lung cancer, present data at scientific meetings and pursue pharmaceutical collaborations. The company also noted it has secured more than $8 million in non-dilutive funding to support development of its preclinical and clinical programs. The full press release is available at https://ibn.fm/WuBOf.
ENV-105, the company's lead candidate, is an antibody targeting CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance and restore effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, addressing significant unmet medical needs. As of the date of this press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.
The mid-year update underscores Kairos Pharma's commitment to leveraging structural biology to overcome drug resistance and immune suppression in cancer. Based in Los Angeles, California, the company is at the forefront of oncology therapeutics. With the proposed acquisition of CL-741, Kairos Pharma broadens its pipeline to include a targeted oral therapy, potentially addressing a wider range of cancers. The CL-741 program is Phase 1-ready, suggesting a near-term catalyst for the company.
Investors can find the latest news and updates relating to KAPA in the company's newsroom at https://ibn.fm/KAPA. The company's progress in securing non-dilutive funding and advancing clinical trials positions it to potentially deliver value to shareholders and address critical needs in oncology.
